Inhibitory effect of Schisandrin on the pharmacokinetics of poziotinib in vivo and in vitro by UPLC‐MS/MS

BACKGROUND: As a pan‐HER tyrosine kinase inhibitor with a promising application prospect, poziotinib is likely to be coadministered with Schisandrins in clinical treatment due to its anticancer activities. METHODS: Eighteen Sprague–Dawley rats were randomly divided into three groups: Schisandrin A g...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shuanghu, Xia, Mengming, Wang, Yu, Lu, Zebei, Geng, Peiwu, Dai, Dapeng, Zhou, Yunfang, Wu, Qingjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175034/
https://www.ncbi.nlm.nih.gov/pubmed/36973912
http://dx.doi.org/10.1111/1759-7714.14870

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175034/
https://www.ncbi.nlm.nih.gov/pubmed/36973912
http://dx.doi.org/10.1111/1759-7714.14870

Ejemplares similares